Effects of bulevirtide on atherosclerosis in an ApoE-deficient mouse model
PLOS One · 2026
DOI: 10.1371/journal.pone.0349211 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Jonas Rusnak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology and Pneumology, Heidelberg University, Medical Faculty Heidelberg/Heidelberg University Hospital Internal Medicin…. Hauptthemen laut MEDLINE: Atherosclerosis, Apolipoproteins E. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Maxwell Biotech Group, Bundesministerium für Bildung und Forschung.
Abstract (Originalsprache)
Objective
Bile acids are known to have a positive impact on atherosclerosis. The study investigates the impact of sodium taurocholate co-transporting polypeptide (NTCP) inhibition with bulevirtide, organic anion transporting polypeptide (OATP) inhibition with rifampicin, and their combination on bile acid levels and atherosclerosis in apolipoprotein E–deficient (ApoE⁻/⁻) mice.
Methods
Fifty-six female ApoE⁻/⁻ mice on a Western type diet were treated daily for four weeks with bulevirtide (5 mg/kg), rifampicin (20 mg/kg), a combination of both, or vehicle. Plasma bile acids and lipids were measured at sacrifice. Atherosclerotic lesion size was quantified in the aortic sinus, and macrophage content was analyzed by Mac-2 immunohistochemistry.
Results
Plasma cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglyceride levels remained unchanged across all groups, being accompanied with no changes of atherosclerotic lesion size (p = 0.896). However, treatment with bulevirtide (p = 0.017), rifampicin (p = 0.003), but mostly their combination (p < 0.001) significantly increased plasma bile acid concentrations and altered the macrophage-to-lesion area ratio, at least for the combination therapy group (p = 0.020). The combined treatment exhibited the highest bile acid levels, indicating additive effects of dual transporter inhibition.
Conclusions
While lesion sizes remained unaffected, the combined NTCP and OATP inhibition significantly enhanced bile acid levels and reduced macrophage content in early atherosclerotic lesions of ApoE⁻/⁻ mice. These results highlight the association of bile acid with the modulation of plaque composition as a potential therapeutic mode of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Angiology and Pneumology, Heidelberg University, Medical Faculty Heidelberg/Heidelberg University Hospital Internal Medicine III, Heidelberg, Germany.
- DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg, Germany.
- Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg/Heidelberg University Hospital Internal Medicine IX, Heidelberg, Germany.
- DZIF (German Center for Infection Research), Partner Site Heidelberg, Heidelberg, Germany.
ORCID-Profile: Jonas Rusnak, Victoria Delcheva, Michael R Preusch
Förderung
- Maxwell Biotech Group
- Bundesministerium für Bildung und Forschung
Zitieren
APA
Rusnak, J., Delcheva, V., Theile, D., Blank, A., Frey, N., & Preusch, M. R. (2026). Effects of bulevirtide on atherosclerosis in an ApoE-deficient mouse model. PLOS One. https://doi.org/10.1371/journal.pone.0349211
Vancouver
Rusnak J, Delcheva V, Theile D, Blank A, Frey N, Preusch MR. Effects of bulevirtide on atherosclerosis in an ApoE-deficient mouse model. PLOS One. 2026. doi:10.1371/journal.pone.0349211
BibTeX
@article{Rusnak2026,
author = {Rusnak, Jonas and Delcheva, Victoria and Theile, Dirk and Blank, Antje and Frey, Norbert and Preusch, Michael R},
title = {Effects of bulevirtide on atherosclerosis in an ApoE-deficient mouse model},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0349211}
}
EUVIMED